



American
Urological
Association

Education & Research, Inc.

Advancing Urology™



The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Friday, April 25, 2025

Agenda:

- | | |
|-------------------------|--|
| 8:15 – 8:20 a.m. | Welcome
<i>TBD, Chair, AUA Office of Education</i>
<i>TBD, SUO</i>
<i>Michael S. Cookson, MD, MMHC & David F. Jarrard, MD</i> |
| 8:20 – 8:40 a.m. | Introduction and Pre-Test
<i>Michael S. Cookson, MD, MMHC & David F. Jarrard, MD</i> |
| 8:40 – 8:55 a.m. | Multidisciplinary Care Model – Rationale and Approach for Building Your Team
<i>Kelvin A. Moses, MD, PhD</i> |
| 8:55 – 9:15 a.m. | Identification and Management after Failure of Local Prostate Cancer Treatments
<i>Stephen A. Boorjian, MD</i> |
| 9:15 – 9:40 a.m. | Genetic Testing in Advanced Prostate Cancer
<i>Leonard Gomella, MD, FACS</i> |
| 9:40 – 10:00 a.m. | Next Generation Imaging (PSMA) and Introduction to Theranostics
<i>Kelly L. Stratton, MD</i> |
| 10:00 – 10:15 a.m. | BREAK |
| 10:15 – 11:05 a.m. | Case-based Roundtable Discussions <ul style="list-style-type: none"> • Case #1 – BCR in a High Risk Patient – <i>Stephen A. Boorjian, MD</i> • Case #2 – Genetic Testing – <i>Kelvin A. Moses, MD, PhD</i> |
| 11:05 – 11:25 a.m. | Manipulating the Androgen Axis: Androgen Receptor Pathway Inhibitors in HSPC and CRPC
<i>David F. Jarrard, MD</i> |
| 11:25 – 11:45 a.m. | mHSPC: Chemo-hormonal Therapy and Treatment Intensification
<i>Pedro Barata, MD, MSc, FACP</i> |
| 11:45 a.m. – 12:35 p.m. | Case-based Roundtable Discussions <ul style="list-style-type: none"> • Case #3 – M1 HSPC – Oligometastatic - <i>David F. Jarrard, MD</i> |



American
Urological
Association

Education & Research, Inc.

Advancing Urology™



12:35 – 1:50 p.m.	• Case #4 – mHSPC High Volume and High Risk - <i>Pedro Barata, MD, MSc, FACP</i> A Non-CME Lunch Symposium supported by TBD* Title TBD <i>Speaker TBD</i> *Lunch Symposium will be held in Room TBD
1:50 – 2:10 p.m.	M0 CRPC: Treatment Options and Goals of Therapy <i>Michael S. Cookson, MD, MMHC</i>
2:10 – 2:40 p.m.	M1 CRPC: First and Second Line Treatment Options <i>Alicia Morgans, MD, MPH</i>
2:40 – 3:10 p.m.	M1 CRPC: PARP Inhibitors and Precision Medicine <i>Kristen R. Scarpato, MD, MPH</i>
3:10 – 3:25 p.m.	BREAK
3:25 – 3:55 p.m.	M1 CRPC: Treatment Sequencing and Future Directions <i>Alicia Morgans, MD, MPH</i>
3:55 – 4:55 p.m.	Case-based Roundtable Discussions • Case #5 – M1 CRPC Minimally Symptomatic – <i>Kelly L. Stratton, MD</i> • Case #6 – M1 CRPC DDR Mutation - First Line - <i>Kristen R. Scarpato, MD, MPH</i> • Case #7 – M1 CRPC - Second & Third Line Therapy - <i>Alicia Morgans, MD, MPH</i>
4:55 – 5:15 p.m.	Post-Test <i>Michael S. Cookson, MD, MMHC & David F. Jarrard, MD</i>
5:15 p.m.	Adjourn